Amyloid-Journal of Protein Folding Disorders

Papers
(The TQCC of Amyloid-Journal of Protein Folding Disorders is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee282
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee150
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial131
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis71
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis60
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines56
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group35
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres29
Association between spinal stenosis and wild-type ATTR amyloidosis27
Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies25
New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden20
Amyloidosis from the patient perspective: the French daily impact of amyloidosis study19
Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience18
Cerebral amyloid angiopathy in a 51-year-old patient with embolization by dura mater extract and surgery for nasopharyngeal angiofibroma at age 1715
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)15
Clinicopathological features of clinically undiagnosed sporadic transthyretin cardiac amyloidosis: a forensic autopsy-based series14
Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)13
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure13
A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis13
Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience12
Metabolomics analysis for diagnosis and biomarker discovery of transthyretin amyloidosis12
Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease12
Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy12
Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type11
Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial10
The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients10
The role of serial 99mTc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis9
Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan: evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis9
Lysozyme amyloidosis—a report on a large German cohort and the characterisation of a novel amyloidogenic lysozyme gene variant9
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays9
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study9
Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study9
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study8
Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain8
The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre8
CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis7
Early events in light chain aggregation at physiological pH reveal new insights on assembly, stability, and aggregate dissociation7
Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients?7
Full-length TDP-43 and its C-terminal domain form filaments in vitro having non-amyloid properties7
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis7
Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation7
Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis6
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay6
Utilization and tolerance of beta-blockers among patients with AL amyloidosis6
Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis6
Reduction in 99m Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy6
Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis6
Identification of AL proteins from 10 λ-AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue6
Beyond Val30Met transthyretin (TTR): variants associated with age-at-onset in hereditary ATTRv amyloidosis6
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange6
0.014764070510864